|
GLIMEPIRIDE | ||
PRODUCT IDENTIFICATION |
||
CAS NO. | 93479-97-1 |
|
EINECS NO. | ||
FORMULA | C24H34N4O5S | |
MOL WT. | 490.62 | |
H.S. CODE |
||
TOXICITY |
||
SMILES |
|
|
SYNONYMS | Amaryl; Glimepirid; Glimepirida; Glimepiridum; | |
1-[[p-[2-(3-ethyl-4-methyl-2-oxo-3-pyrroline-1-carboxamido) ethyl]phenyl] sulfonyl]-3-(trans-4- methyl cyclohexyl) Urea; trans-2,5-Dihydro-3-ethyl-4-methyl-N-(2-(4-(((((4-methylcyclohexyl)amino) carbonyl)amino)sulfonyl)phenyl)ethyl)-2-oxo-1H-pyrrole-1-carboxamide; Endial; |
||
CLASSIFICATION |
HYPOGLYCEMIC AGENTS / IMMUNOSUPPRESSIVE AGENTS / | |
PHYSICAL AND CHEMICAL PROPERTIES |
||
PHYSICAL STATE | white to yellowish crystalline powder | |
MELTING POINT | 188 - 192 C | |
BOILING POINT | ||
SPECIFIC GRAVITY | ||
SOLUBILITY IN WATER | ||
pH | ||
VAPOR DENSITY |
| |
AUTOIGNITION |
| |
NFPA RATINGS |
||
REFRACTIVE INDEX |
||
FLASH POINT |
| |
STABILITY | Stable under ordinary conditions. | |
GENERAL DESCRIPTION & APPLICATIONS |
||
Sulfonylureas: a class of oral hypoglycaemic agents that exert hypoglycemic
activity by stimulating the pancreas to secrete more insulin, active in type II
diabetes only. Sulfonylureas have a phenyl ring nucleus with two branched chains
in chemical structure. They can can induce hypoglycemia which is potential life
threatening side effect in case of over-dose.
Glimepiride, belongs to the class of sulfonylurea, is an oral blood-glucose-lowering drug actong for medium- to-long period. It is a white to yellowish crystalline powder with odorless; melting point 205 -207 C. The chemical designation is 1-[[p-[2-(3-ethyl-4-methyl-2-oxo-3-pyrroline-1-carboxamido) ethyl]phenyl] sulfonyl]-3-(trans-4-methylcyclohexyl) Urea. Some classes of drugs of anti-diabete include:
|
||
SALES SPECIFICATION | ||
APPEARANCE |
white to yellowish crystalline powder | |
ASSAY (HPLC) |
99.0% min | |
MELTING POINT |
205 - 207 C |
|
LOSS ON DRYING |
0.5% max |
|
TOTAL IMPURITY |
1.0% max |
|
HEAVY METALS |
20ppm max |
|
TRANSPORTATION | ||
PACKING |
| |
HAZARD CLASS | ||
UN NO. | ||
OTHER INFORMATION | ||
|
|